These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23665018)

  • 1. AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis.
    Li CH; Zhao JX; Sun L; Yao ZQ; Deng XL; Liu R; Liu XY
    Biochem Biophys Res Commun; 2013 Jun; 435(4):533-9. PubMed ID: 23665018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL downregulates cell surface CXCR6 expression through JAK2/STAT3 signaling pathway during osteoclastogenesis.
    Li C; Zhao J; Sun L; Yao Z; Liu R; Huang J; Liu X
    Biochem Biophys Res Commun; 2012 Dec; 429(3-4):156-62. PubMed ID: 23142594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
    Tsuji-Naito K
    Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
    Wu Q; Zhou X; Huang D; Ji Y; Kang F
    Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.
    Duplomb L; Baud'huin M; Charrier C; Berreur M; Trichet V; Blanchard F; Heymann D
    Endocrinology; 2008 Jul; 149(7):3688-97. PubMed ID: 18403479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
    Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
    PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
    J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
    Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
    Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
    Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
    Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
    Huang H; Chang EJ; Ryu J; Lee ZH; Lee Y; Kim HH
    Biochem Biophys Res Commun; 2006 Dec; 351(1):99-105. PubMed ID: 17052691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL.
    Park CK; Lee Y; Chang EJ; Lee MH; Yoon JH; Ryu JH; Kim HH
    Biochem Pharmacol; 2008 Jun; 75(11):2175-82. PubMed ID: 18433733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cIAP1/2 negatively regulate RANKL-induced osteoclastogenesis through the inhibition of NFATc1 expression.
    Yamaguchi N; Yokota M; Taguchi Y; Gohda J; Inoue J
    Genes Cells; 2012 Dec; 17(12):971-81. PubMed ID: 23126497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.